Sputnik V Vaccine Induces Seroconversion and Neutralizing Capacity: Insights from Argentine Research

Highlights

The first dose of Sputnik V results in a 94% seroconversion rate in naïve individuals.
A second dose greatly increases antibody titers and neutralizing capacity.
One dose in seropositive individuals produces higher titers than two doses in previously untreated patients.
There is no obvious benefit to using a second dose in previously infected individuals.

Sputnik V Vaccine Induces Seroconversion and Neutr

Summary

Mass vaccination offers great promise to stop the global COVID-19 pandemic. However, limited supply and uneven distribution of the vaccine create an urgent need to optimize vaccination strategies.

We evaluated SARS-CoV-2-specific antibody responses following Sputnik V vaccination of healthcare workers in Argentina, measuring anti-spike IgG titers and neutralizing capacity after one and two doses in a cohort of inexperienced or previously infected volunteers.

By 21 days after receiving the first dose of the vaccine, 94% of naïve participants develop spike-specific IgG antibodies.

A single dose of Sputnik V elicits higher levels of antibodies and virus-neutralizing capacity in previously infected individuals than in those who have not received the full two-dose schedule.

The high seroconversion rate after a single dose in naïve participants suggests a benefit of delaying administration of the second dose to increase the number of people vaccinated.

The data presented provide information to guide public health decisions in light of the current global health emergency.

Sputnik V Vaccine Induces Seroconversion and Neutralizing Capacity: Insights from Argentine Research

Argentine investigation published in Cell Reports Medicine demonstrates that the Sputnik V vaccine induces seroconversion and neutralizing capacity, contributing to the growing body of evidence supporting the safety and efficacy of this COVID-19 vaccine candidate.